Fundamental Analysis: AGILENT TECHNOLOGIES (#A)

Agilent Technologies, Inc. (#A) is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California. Agilent was established in 1999 as a spin-off from Hewlett-Packard.

The Company delivers complete scientific solutions, helping customers achieve superior outcomes in their labs, clinics, business and the world they seek to improve. It does it by focusing on the manufacturing of measuring, electronic medical equipment and equipment for chemical analysis.

💡 Agilent reported better than consensus forecasts: revenue grew by 8% (exceed expectations by + 2%). The pandemic environment gave the company a +2% growth and expansions in end markets.

👉🏻 Overall, the biopharmaceutical business performed well with a 12% increase in revenue, in addition #A reported double-digit growth in Biotechnology together with a 2% increase in NASD (Nucleic Acid Development Solutions) sales without significant cost increases.

👉🏻 The Power Solutions business line is also not far behind: in fact, thanks to strong sales in China, it has been growing 16% .

👉🏻 The Chemical Engineering Division has more potential to grow while increasing costs and maintaining a pandemic co-factor: Management is forecasting 1.5-2% revenue growth for the division in 2021 (in line with the last few quarters).

The company predicts a 4% to 6% revenue growth from operating activities and $ 3.57-3.67 EPS (versus $ 3.69 consensus):

Biopharmaceutical business is forecasting 7-9% revenue growth

Food and Diagnostics Solutions expects a growth by 4-6%

The subdivision of developments for ecology and forensic examination see a 1-3% growth

The segment of development for scientific research expects growth by 1-3%

The chemical engineering subdivision - unchanged.

⚡️ On a latest stock note, J.P. Morgan recommends buying Agilent shares and raises its target price at $ 125

🎯 Target price - $ 125, upside potential + 5.2%.

OTB Global Investments

London, 11 December 2020